{"id":66002,"date":"2026-05-22T22:14:53","date_gmt":"2026-05-22T14:14:53","guid":{"rendered":"https:\/\/flcube.com\/?p=66002"},"modified":"2026-05-22T22:14:54","modified_gmt":"2026-05-22T14:14:54","slug":"merck-kgaa-launches-phase-iii-proceade-crc-03-trial-for-first-in-class-ceacam5-adc-precemtabart-tocentecan-in-metastatic-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66002","title":{"rendered":"Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Merck KGaA (<a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:ETR\">ETR: MRK<\/a>)<\/strong> announced the initiation of the <strong>Phase III PROCEADE-CRC-03 study<\/strong>, evaluating the safety and efficacy of <strong>precemtabart tocentecan (Precem TcT)<\/strong>, an <strong>anti-CEACAM5 antibody-drug conjugate (ADC)<\/strong>, in patients with <strong>metastatic colorectal cancer (mCRC)<\/strong>. The investigational therapy represents the <strong>first CEACAM5-targeted ADC<\/strong> conjugated with an <strong>exatecan payload<\/strong>, leveraging Merck&#8217;s proprietary <strong>linker-payload technology<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-clinical-development-milestone\" class=\"wp-block-heading\">Clinical Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Sponsor<\/strong><\/td><td>Merck KGaA (ETR: MRK)<\/td><\/tr><tr><td><strong>Study Name<\/strong><\/td><td>PROCEADE-CRC-03<\/td><\/tr><tr><td><strong>Phase<\/strong><\/td><td>Phase III<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Precemtabart tocentecan (Precem TcT) \u2013 anti-CEACAM5 ADC<\/td><\/tr><tr><td><strong>Target Indication<\/strong><\/td><td>Metastatic colorectal cancer (mCRC)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>CEACAM5-positive mCRC patients<\/td><\/tr><tr><td><strong>Primary Endpoints<\/strong><\/td><td>Safety and efficacy (specific endpoints not disclosed)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-technological-innovation\" class=\"wp-block-heading\">Drug Profile &amp; Technological Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Antigen:<\/strong> CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5)<\/li>\n\n\n\n<li><strong>Payload:<\/strong> Exatecan \u2013 potent topoisomerase I inhibitor (TOP1i)<\/li>\n\n\n\n<li><strong>Linker Technology:<\/strong> Merck&#8217;s proprietary linker-payload system<\/li>\n\n\n\n<li><strong>Key Innovation:<\/strong> First CEACAM5 ADC utilizing exatecan payload<\/li>\n\n\n\n<li><strong>Mechanism Design:<\/strong> Engineered for stability in systemic circulation while maintaining potent cancer cell-killing activity<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> CEACAM5 is highly expressed in colorectal cancer and associated with poor prognosis<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-development-context\" class=\"wp-block-heading\">Strategic Development Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Unmet Need<\/strong><\/td><td>Limited effective therapies for refractory mCRC; median survival remains under 30 months<\/td><\/tr><tr><td><strong>Target Validation<\/strong><\/td><td>CEACAM5 expressed in 80\u201390% of colorectal cancers, making it an attractive therapeutic target<\/td><\/tr><tr><td><strong>Payload Advantage<\/strong><\/td><td>Exatecan derivatives have demonstrated superior potency compared to traditional TOP1 inhibitors<\/td><\/tr><tr><td><strong>Competitive Positioning<\/strong><\/td><td>First-in-class CEACAM5-exatecan ADC; differentiates from other ADC platforms<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>Validates Merck&#8217;s linker-payload technology for next-generation ADC development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The PROCEADE-CRC-03 trial builds on promising preclinical and early clinical data demonstrating that precemtabart tocentecan&#8217;s innovative design achieves targeted delivery of a highly potent cytotoxic agent specifically to CEACAM5-expressing tumor cells while minimizing systemic toxicity.<\/p>\n\n\n\n<h2 id=\"h-market-opportunity-amp-commercial-implications\" class=\"wp-block-heading\">Market Opportunity &amp; Commercial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global mCRC Burden:<\/strong> Approximately 1.9 million new colorectal cancer cases annually worldwide, with 20\u201325% presenting as metastatic disease<\/li>\n\n\n\n<li><strong>Addressable Population:<\/strong> Estimated 70\u201380% of mCRC patients express CEACAM5 at levels suitable for targeted therapy<\/li>\n\n\n\n<li><strong>Current Treatment Landscape:<\/strong> Standard care includes chemotherapy combinations, EGFR inhibitors (for RAS wild-type), and immune checkpoint inhibitors (for MSI-H tumors)<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Peak annual sales potential of \u20ac500\u2013700 million if approved for broad mCRC population<\/li>\n\n\n\n<li><strong>Pipeline Strategy:<\/strong> Success would establish Merck as a leader in next-generation ADC technology and expand oncology portfolio beyond current immuno-oncology focus<\/li>\n\n\n\n<li><strong>Partnership Opportunities:<\/strong> Positive Phase III data could attract commercial partnership interest from global oncology-focused pharmaceutical companies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-development-timeline\" class=\"wp-block-heading\">Forward Development Timeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase III Enrollment:<\/strong> Expected to complete by Q4 2028<\/li>\n\n\n\n<li><strong>Primary Completion:<\/strong> Data readout anticipated in H2 2029<\/li>\n\n\n\n<li><strong>Regulatory Strategy:<\/strong> Simultaneous submissions planned for EMA, FDA, and other major regulatory agencies<\/li>\n\n\n\n<li><strong>Manufacturing Scale-up:<\/strong> Already initiated to support potential commercial launch<\/li>\n\n\n\n<li><strong>Companion Diagnostic:<\/strong> Co-development of CEACAM5 expression assay underway with leading diagnostic partner<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, market opportunities, and commercial expectations for precemtabart tocentecan. Actual results may differ due to risks including clinical trial outcomes, regulatory review processes, competitive developments, and market dynamics in the oncology space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck KGaA (ETR: MRK) announced the initiation of the Phase III PROCEADE-CRC-03 study, evaluating the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,16,62,120],"class_list":["post-66002","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-clinical-trial-approval-initiation","tag-merck"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck KGaA (ETR: MRK) announced the initiation of the Phase III PROCEADE-CRC-03 study, evaluating the safety and efficacy of precemtabart tocentecan (Precem TcT), an anti-CEACAM5 antibody-drug conjugate (ADC), in patients with metastatic colorectal cancer (mCRC). The investigational therapy represents the first CEACAM5-targeted ADC conjugated with an exatecan payload, leveraging Merck&#039;s proprietary linker-payload technology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66002\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer\" \/>\n<meta property=\"og:description\" content=\"Merck KGaA (ETR: MRK) announced the initiation of the Phase III PROCEADE-CRC-03 study, evaluating the safety and efficacy of precemtabart tocentecan (Precem TcT), an anti-CEACAM5 antibody-drug conjugate (ADC), in patients with metastatic colorectal cancer (mCRC). The investigational therapy represents the first CEACAM5-targeted ADC conjugated with an exatecan payload, leveraging Merck&#039;s proprietary linker-payload technology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66002\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-22T14:14:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-22T14:14:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66002#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66002\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer\",\"datePublished\":\"2026-05-22T14:14:53+00:00\",\"dateModified\":\"2026-05-22T14:14:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66002\"},\"wordCount\":489,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Merck\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66002#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66002\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66002\",\"name\":\"Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-22T14:14:53+00:00\",\"dateModified\":\"2026-05-22T14:14:54+00:00\",\"description\":\"Merck KGaA (ETR: MRK) announced the initiation of the Phase III PROCEADE-CRC-03 study, evaluating the safety and efficacy of precemtabart tocentecan (Precem TcT), an anti-CEACAM5 antibody-drug conjugate (ADC), in patients with metastatic colorectal cancer (mCRC). The investigational therapy represents the first CEACAM5-targeted ADC conjugated with an exatecan payload, leveraging Merck's proprietary linker-payload technology.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66002#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66002\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66002#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Merck KGaA (ETR: MRK) announced the initiation of the Phase III PROCEADE-CRC-03 study, evaluating the safety and efficacy of precemtabart tocentecan (Precem TcT), an anti-CEACAM5 antibody-drug conjugate (ADC), in patients with metastatic colorectal cancer (mCRC). The investigational therapy represents the first CEACAM5-targeted ADC conjugated with an exatecan payload, leveraging Merck's proprietary linker-payload technology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66002","og_locale":"en_US","og_type":"article","og_title":"Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer","og_description":"Merck KGaA (ETR: MRK) announced the initiation of the Phase III PROCEADE-CRC-03 study, evaluating the safety and efficacy of precemtabart tocentecan (Precem TcT), an anti-CEACAM5 antibody-drug conjugate (ADC), in patients with metastatic colorectal cancer (mCRC). The investigational therapy represents the first CEACAM5-targeted ADC conjugated with an exatecan payload, leveraging Merck's proprietary linker-payload technology.","og_url":"https:\/\/flcube.com\/?p=66002","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-22T14:14:53+00:00","article_modified_time":"2026-05-22T14:14:54+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66002#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66002"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer","datePublished":"2026-05-22T14:14:53+00:00","dateModified":"2026-05-22T14:14:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66002"},"wordCount":489,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Cancer","Clinical trial approval \/ initiation","Merck"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66002#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66002","url":"https:\/\/flcube.com\/?p=66002","name":"Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-22T14:14:53+00:00","dateModified":"2026-05-22T14:14:54+00:00","description":"Merck KGaA (ETR: MRK) announced the initiation of the Phase III PROCEADE-CRC-03 study, evaluating the safety and efficacy of precemtabart tocentecan (Precem TcT), an anti-CEACAM5 antibody-drug conjugate (ADC), in patients with metastatic colorectal cancer (mCRC). The investigational therapy represents the first CEACAM5-targeted ADC conjugated with an exatecan payload, leveraging Merck's proprietary linker-payload technology.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66002#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66002"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66002#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66002","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66002"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66002\/revisions"}],"predecessor-version":[{"id":66004,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66002\/revisions\/66004"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66002"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66002"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66002"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}